Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zoom
ZM
|
+$806M |
| 2 |
AbbVie
ABBV
|
+$481M |
| 3 |
T-Mobile US
TMUS
|
+$464M |
| 4 |
Kroger
KR
|
+$430M |
| 5 |
Baidu
BIDU
|
+$423M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$1.35B |
| 2 |
AGN
Allergan plc
AGN
|
+$1.26B |
| 3 |
S
Sprint Corporation
S
|
+$675M |
| 4 |
Amgen
AMGN
|
+$488M |
| 5 |
Humana
HUM
|
+$450M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 23.45% |
| 2 | Technology | 16.09% |
| 3 | Consumer Staples | 10.57% |
| 4 | Consumer Discretionary | 9.95% |
| 5 | Communication Services | 9.52% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3001
Aldeyra Therapeutics
ALDX
$91.7M
| $332K | ﹤0.01% |
79,618
-516,782
| -87% | -$1.89M |
|
3002
Taylor Devices
TAYD
$172M
| $332K | ﹤0.01% |
33,235
+4,100
| +14% | +$42K |
|
3003
Alerus Financial
ALRS
$843M
| $331K | ﹤0.01% |
16,765
+2,800
| +20% | +$50.4K |
|
3004
Hope Bancorp
HOPE
$1.83B
| $331K | ﹤0.01% |
35,864
-104,036
| -74% | -$932K |
|
3005
iShares Global Tech ETF
IXN
$9.47B
| $330K | ﹤0.01% |
+8,400
| New | +$297K |
|
|
FM
3006
DELISTED
iShares Frontier and Select EM ETF
FM
| $327K | ﹤0.01% |
13,500
+100
| +0.7% | +$2.29K |
|
3007
Innospec
IOSP
$2.29B
| $324K | ﹤0.01% |
4,200
-12,100
| -74% | -$885K |
|
3008
Polaris
PII
$3.9B
| $324K | ﹤0.01% |
3,500
-289,211
| -99% | -$22M |
|
|
REED
3009
DELISTED
Reeds, Inc. Common Stock
REED
| $324K | ﹤0.01% |
+6,764
| New | +$240K |
|
|
RPT
3010
Rithm Property Trust
RPT
$99.9M
| $323K | ﹤0.01% |
+5,856
| New | +$286K |
|
3011
Artivion
AORT
$1.39B
| $322K | ﹤0.01% |
+16,800
| New | +$356K |
|
|
HIL
3012
DELISTED
Hill International, Inc. Common Stock
HIL
| $322K | ﹤0.01% |
211,589
-105,800
| -33% | -$177K |
|
|
RIBT
3013
DELISTED
RiceBran Technologies
RIBT
| $322K | ﹤0.01% |
38,885
+720
| +2% | +$7.89K |
|
3014
iShares International Treasury Bond ETF
IGOV
$1.54B
| $321K | ﹤0.01% |
+6,300
| New | +$314K |
|
3015
Bank7 Corp
BSVN
$495M
| $320K | ﹤0.01% |
+29,521
| New | +$273K |
|
3016
Palisade Bio
PALI
$342M
| $320K | ﹤0.01% |
99
+16
| +19% | +$57.8K |
|
|
SLNO
3017
DELISTED
Soleno Therapeutics
SLNO
| $320K | ﹤0.01% |
9,617
+1,853
| +24% | +$80.3K |
|
3018
Invesco NASDAQ Internet ETF
PNQI
$544M
| $319K | ﹤0.01% |
+9,000
| New | +$279K |
|
3019
Vanguard S&P 500 Growth ETF
VOOG
$27.4B
| $318K | ﹤0.01% |
+10,200
| New | +$294K |
|
3020
FVCBankcorp
FVCB
$337M
| $317K | ﹤0.01% |
36,876
-11,500
| -24% | -$101K |
|
3021
Limbach Holdings
LMB
$536M
| $317K | ﹤0.01% |
85,617
+700
| +0.8% | +$2.19K |
|
|
ICON
3022
DELISTED
Iconix Brand Group, Inc.
ICON
| $317K | ﹤0.01% |
340,678
-21,000
| -6% | -$18.5K |
|
3023
Lear
LEA
$8.16B
| $316K | ﹤0.01% |
2,900
-6,500
| -69% | -$647K |
|
3024
Direxion Daily S&P 500 Bear 1X ETF
SPDN
$198M
| $315K | ﹤0.01% |
+13,800
| New | +$338K |
|
3025
City Holding Co
CHCO
$2.07B
| $313K | ﹤0.01% |
4,800
-8,400
| -64% | -$532K |
|
Similar funds
Jim Simons's Q2 2020 Portfolio in Review
As of Q2 2020, Jim Simons held 3,987 positions worth $116B, up 13% from $103B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
Jim Simons withdrew a net $8.24B in Q2 2020, closing 596 positions and reducing 1,366 holdings. Its most notable exit was Allergan plc, an estimated $1.26B position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 23% of assets, down from 25% a quarter earlier, followed by Technology and Consumer Staples.
Against the trend, Jim Simons opened a new position in Uber worth $187M.
- Jim Simons's largest Q2 2020 buy was Uber: 6,030,316 shares worth $187M.
- Jim Simons added most to Zoom in Q2 2020, an estimated $806M increase.
- Jim Simons's biggest Q2 2020 reduction was Bristol-Myers Squibb, cutting an estimated $1.35B.
- Jim Simons fully exited Allergan plc in Q2 2020, selling an estimated $1.26B.
- Jim Simons's ten largest holdings make up 14% of its $116B portfolio in Q2 2020.
- Jim Simons opened 584 new positions and closed 596 in Q2 2020.
- Jim Simons's portfolio value rose 13% quarter-over-quarter to $116B.
Based on Renaissance Technologies's 13F filing for Q2 2020, filed 13 Aug 2020.